NCT03656562ianalumabsystemic lupus erythematosusSLESRI-6SRI-4
…s This multi-center, randomized, parallel-group Phase 2 study ( NCT03656562) enrolled patients with anti-nuclear antibodies >=1:80, 11 ACR …
5,089articles mentioning funders
9,137funder mentions
3,238distinct funders extracted
0%of mentions human-reviewed
All extracted funders
Showing 1,201–1,260 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.
Drug Agencies1Drug Enforcement Administration1Dudley Group National Health Service1Dutch Employee Insurance Agency1EAHP1EASL1EAT-Lancet Commission1EATC1EBSCO CINAHL1EBSCO Open Dissertation1EC-20250506-041ECCO-ESPGHAN1ECRI Guidelines Trust1EFSD/Boehringer Ingelheim European Research Programme1EMBASE Ovid1EMD Serono1EMIS Health1EOPCN1EPHOR1EPI1EPSRC Cambridge Maths in Healthcare1ER/GLP28/41ERC # 2025-11293-351571ERN_1775-Jul20241ESGE1ESMINT Pilot Research Grant1ETH2223-02251ETH2324-09391EU CTIS trial register1EU HEALTH1EU budget1EU-CoWork1EU-funded1EU-funded projects BOOST1EU-trial-number 2023-510186-981Early Access to Medicine Scheme1East Kent University Hospitals NHS Foundation Trust1East Lancashire Hospice1East Midlands Nottingham 1 Research Ethics Committee1East Midlands-Leicester South Research Ethics Committee1East Midlands—Derby Research Ethics Committee1East of England–Cambridge South Research Ethics Committee1Eastern Cooperative Oncology Group1EconLit1Edinburgh Innovation Fellowship1Edith Busch Stiftung1Edwards Lifesciences LLC1Ehlers-Danlos Support UK1Eli Lilly1Eli Lilly and Company1Elizabeth Glaser Paediatric AIDS Foundation1Embase.com1Employees’ Health Insurance1English NHS1English NHS Ambulance Trust1Entidades Promotoras de Salud1Environmental Protection Administration1Envision Pharma, Inc.1Eppdata GmbH1Epsilon Medical1
Articles mentioning funders
5,089 articles · page 252 of 425NCT04221477obinutuzumabCOVID-19lupus nephritisLNOBI
…Objectives The REGENCY trial ( NCT04221477) evaluated obinutuzumab plus standard therapy (OBI+ST) compared…
NCT05638802SLEDS-7011a
…randomized, placebo-controlled, double-blind Phase 1b/2 study [ NCT05638802]. Patients were: 1) globally enrolled and randomized 2:1 to DS-…
NCT05162586EnpatoranlupusSLE
…-blind, placebo-controlled, dose-finding basket study (WILLOW [ NCT05162586]), enpatoran provided clinically meaningful improvements in cut…
81.4%
GSKbelimumabSLEGSKstandard therapy
…ing belimumab treatment earlier in the disease course. Funding: GSK, Original presentation: ACR 2025…
GSKLNSLEBelimumabcyclophosphamidemycophenolate mofetilBLISS-LNCYCBELMMF
…tion maintenance data to support LN treatment decisions.Funding GSK (BEL114054, NCT01639339)Original presentation: ASN 2025…
Uber HealthSystemic lupus erythematosusUniversity of North CarolinaPharmacist counselingUNCtransportation support
…gift card and to 1 patient through direct ride coordination via Uber Health.Conclusions This work highlights the impact of barriers to heal…
Facebook support grouphydroxychloroquineSLEtunisian SLE
…ional study with an anonymous online questionnaire form via the Facebook support group for tunisian SLE patients. The questionnaire included sections …
NCT04221477obinutuzumablupus nephritisOBILNPBO
…Objectives The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard t…
NCT04294667dapirolizumab pegolSLEDZPLupusprednisonePBO
…luding sustained outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor wi…
PFMDLupus Europesystemic lupus erythematosusAnn Rheum DisSLEAutoimmun RevLupus
… by the Best emerging innovation award assigned in June 2025 by PFMD to Lupus GPT.Conclusions LupusGPT embodies a tangible result th…
NCT05162586lupusEnpatoranSLECLE/SLE
… 2 randomised, double-blind, placebo-controlled study (WILLOW [ NCT05162586]), enpatoran reduced disease activity in participants with cuta…